In line with our findings in ALL, a recent study also found heterogeneous sensitivity of diffuse large B-cell lymphoma cells to inhibitors of BCL-2, BCL-XL and MCL-1 [38]. The gene discussed is BCL2L1; the disease is acute lymphoblastic leukemia.